Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis, Inc. (NASDAQ: CRIS) is a biotechnology company that publicly describes its focus as the development of emavusertib (CA-4948), an orally available small molecule inhibitor of IRAK4 and, in some disclosures, FLT3. The Curis news stream highlights clinical progress, financing events, and corporate updates that shape the company’s development plans and capital position.
News about Curis frequently covers clinical data and study milestones for emavusertib. The company has reported interim results from its frontline AML triplet study (emavusertib with venetoclax and azacitidine), updates from the TakeAim Lymphoma and TakeAim Leukemia Phase 1/2 trials in PCNSL, AML and high-risk MDS, and presentations at major medical meetings such as the American Society of Hematology (ASH), the Society for Neuro-Oncology (SNO), and ASCO. These releases often describe response measures such as minimal residual disease status and safety observations within defined patient cohorts.
Investors following CRIS news will also see financing and capital markets announcements, including registered direct offerings, concurrent private placements of pre-funded and common warrants, and a PIPE financing involving Series B convertible preferred stock and multiple warrant series. Curis’s news has detailed the structure of these transactions, the gross proceeds, and the stated use of funds for research and development, general corporate purposes, and working capital.
Additional news items address corporate and regulatory developments, such as business updates, quarterly financial results, inducement equity grants, conference participation, and Nasdaq listing compliance notices related to market value of listed securities requirements. For readers tracking Curis, the CRIS news page provides an organized view of these clinical, financial, and listing-related disclosures in one place, allowing users to review how trial data, capital raises, and regulatory interactions evolve over time.
Curis (NASDAQ: CRIS) announced promising preliminary results from its Phase 1 study of CA-4948, an IRAK4 kinase inhibitor targeting acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Key findings include marrow blast reductions in all evaluable patients, with no dose-limiting toxicities reported. Out of 7 patients, 6 remain in the study. The results highlight CA-4948's potential, especially for patients who are relapsed or refractory. The company plans to provide further updates on the study in mid-2021.
Curis (NASDAQ: CRIS) announced updated data from its Phase 1 study of CA-4948, an IRAK4 kinase inhibitor for relapsed or refractory non-Hodgkin's lymphoma (NHL). Results indicate that the recommended Phase 2 dose of 300 mg BID demonstrates significant anti-cancer activity with a median tumor reduction of 27% in evaluable patients. The drug is well-tolerated, and preliminary data from biomarkers suggest potential for patient enrichment. A virtual presentation of these findings will occur at the 62nd American Society of Hematology Annual Meeting.
Curis, Inc. (NASDAQ: CRIS) announced a virtual KOL event on December 8, 2020, to discuss the IRAK4 kinase inhibitor CA-4948. This event will share progress from the Phase 1 study in patients with non-Hodgkin lymphoma and new clinical data for acute myeloid leukemia and myelodysplastic syndromes. The presentation will be led by James Dentzer, CEO, alongside Dr. Amit Verma. A live webcast will be available, with a replay accessible for 90 days after the event.
Curis, Inc. (NASDAQ: CRIS) reported its third-quarter 2020 financial results with a net loss of $6.0 million ($0.11 per share), an improvement from a loss of $6.4 million in Q3 2019. Total revenues were $2.7 million, slightly down from $2.9 million a year prior. Key operational highlights include ongoing Phase 1 studies for the IRAK4 inhibitor CA-4948 and the anti-VISTA antibody CI-8993. The company also secured a CRADA with NCI for CA-4948’s development and maintains a cash position of $23.6 million, sufficient for operations through mid-2021.
Curis, a biotechnology company (NASDAQ: CRIS), has entered a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to develop CA-4948, an IRAK4 kinase inhibitor for cancer treatment. This collaboration aims to enhance CA-4948's clinical studies and validate Curis's approach to targeted cancer therapeutics. CA-4948 is currently in Phase 1 trials for non-Hodgkin lymphoma and acute myeloid leukemia. The company also plans a combination study with ibrutinib, expected to start in Q4 2020.
Curis, Inc. (NASDAQ: CRIS) announced the acceptance of three abstracts for CA-4948 presentations at the 62nd American Society of Hematology Annual Meeting from December 5-8, 2020. CA-4948 is a first-in-class IRAK4 inhibitor aimed at treating various hematologic malignancies. Data from Phase 1 studies in non-Hodgkin's lymphoma and acute myeloid leukemia are expected by year-end. The company emphasizes progress and will share updated safety and efficacy results during the conference.
Curis, a biotechnology company focused on cancer therapeutics, announced that CEO James Dentzer will present at the H.C. Wainwright & Co. 6th Annual Israel Conference on November 12, 2020, at 12:00 pm ET. A live webcast will be available on Curis' website in the Investors section, with a replay accessible for 90 days post-event.
Curis is advancing multiple cancer treatments, including drugs in collaboration with Aurigene and Genentech. Their pipeline includes CA-4948 for non-Hodgkin lymphoma and acute myeloid leukemia, with ongoing Phase 1 clinical trials.
Curis, Inc. (NASDAQ: CRIS) will report its third quarter 2020 financial results on November 10, 2020, post market close. The management will conduct a conference call at 4:30 p.m. ET on the same day to discuss the results. The call can be accessed via phone or through the Curis website. Curis is known for developing innovative cancer therapeutics and has several key collaborations, including with Aurigene and Genentech for advanced treatment options and ongoing clinical trials.
Curis, Inc. (NASDAQ: CRIS) announced the publication of a research paper in ACS Medicinal Chemistry Letters, detailing CA-4948, an orally bioavailable IRAK4 inhibitor for treating hematologic malignancies. This small molecule demonstrated potent IRAK4 inhibition and showed tumor regression in animal studies without significant toxicity. CA-4948 is currently in Phase 1 trials for non-Hodgkin lymphomas and acute myeloid leukemia. Curis plans to commence a combination study with ibrutinib for non-Hodgkin lymphomas this quarter. Curis emphasizes the need for additional funding to support ongoing operations.
Summary not available.